RESUMO
Recent findings demonstrate that chemokines, and more specifically CC chemokine ligand 2 (CCL2 or monocyte chemoattractant protein-1), play a major role in pain processing. In the present study, we assess nociceptive responses of mice that overexpressed CCL2 under control of glial fibrillary acidic protein promoter (CCL2 tg). In models of acute nociception CCL2 tg mice demonstrated significantly enhanced nociceptive behavior relative to wild-type controls in responses to both thermal (hot plate) and chemical (formalin test) stimulus modalities. There were no differences in mechanical allodynia in the partial sciatic nerve ligation model, in terms of either magnitude or duration of the allodynic response; however, both groups responded to the maximal extent measurable. In a model of inflammatory pain, elicited by intraplantar administration of complete Freund's adjuvant (CFA), CCL2 tg mice displayed both greater edema and thermal hyperalgesia compared with control mice. In control mice, edema and hyperalgesia returned to baseline values 5-7 days post CFA. However, in CCL2 tg mice, thermal hyperalgesia was significantly different from baseline up to 3 weeks post CFA. Parallel to these enhanced behavioral responses CCL2 serum levels were significantly greater in CCL2 overexpressing mice and remained elevated 7 days post CFA. Consequently, proinflammatory cytokine mRNA expression (IL-1beta, IL-6, and TNFalpha) levels were greater in skin, dorsal root ganglia (DRG), and spinal cord, whereas the anti-inflammatory cytokine (IL-10) level was lower in skin and DRG in CCL2 overexpressing mice than in control mice. Taken together with data from CCR2-deficient mice, these present data confirm a key role of CCL2/CCR2 axis in pain pathways and suggest that inhibiting this axis may result in novel pain therapies.
Assuntos
Astrócitos/fisiologia , Quimiocina CCL2/biossíntese , Quimiocina CCL2/fisiologia , Dor/fisiopatologia , Animais , Astrócitos/metabolismo , Quimiocinas/biossíntese , Ensaio de Imunoadsorção Enzimática , Formaldeído , Adjuvante de Freund , Gânglios Espinais/metabolismo , Temperatura Alta , Inflamação/induzido quimicamente , Inflamação/complicações , Inflamação/fisiopatologia , Masculino , Camundongos , Medição da Dor , Traumatismos dos Nervos Periféricos , Doenças do Sistema Nervoso Periférico/complicações , Doenças do Sistema Nervoso Periférico/fisiopatologia , Fenótipo , Estimulação Física , Tempo de Reação/fisiologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Células de Schwann/fisiologia , Medula Espinal/fisiologiaRESUMO
Extensive development of the structure-activity relationships of a screening lead determined three important pharmacophores for gonadotropin-releasing hormone (GnRH) receptor antagonist activity. Incorporation of the 3,4,5-trimethylphenyl group at the 3-position, 2-(2(S)-azetidinyl)ethoxy group at the 4-position, and N-4-pyrimidinylcarboxamide at the 6-position of the quinolone core resulted in the identification of 4-(2-(azetidin-2(S)-yl)ethoxy)-7-chloro-2-oxo-3-(3,4,5-trimethylphenyl)-1,2-dihydroquinoline-6-carboxylic acid pyrimidin-4-ylamide (1) as a potent antagonist of the GnRH receptor. A 10(4)-fold increase in in vitro binding affinity is observed for the GnRH receptor as compared to the initial screening lead. Compound 1 exhibits nanomolar binding activity and functional antagonism at the human receptor and is 7-fold less active at the rhesus receptor. Intravenous administration of compound 1 to rhesus monkeys results in a significant decrease of the serum levels of downstream hormones, luteinizing hormone (79% decrease in area under the curve) and testosterone (92% decrease in area under the curve), at a dose of 3 mg/kg. Quinolone 1 is a potent nonpeptidyl antagonist for the human GnRH receptor that is efficacious for the suppression of luteinizing hormone and testosterone in primates.
Assuntos
Azetidinas/síntese química , Quinolonas/síntese química , Receptores LHRH/antagonistas & inibidores , Animais , Azetidinas/química , Azetidinas/farmacocinética , Azetidinas/farmacologia , Ligação Competitiva , Células CHO , Cricetinae , Humanos , Técnicas In Vitro , Macaca mulatta , Hipófise/metabolismo , Quinolonas/química , Quinolonas/farmacocinética , Quinolonas/farmacologia , Ensaio Radioligante , Ratos , Relação Estrutura-AtividadeRESUMO
The effects of two beta(3)-adrenergic receptor agonists, (R)-4-[4-(3-cyclopentylpropyl)-4,5-dihydro-5-oxo-1H-tetrazol-1-yl]-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]benzenesulfonamide and (R)-N-[4-[2-[[2-hydroxy-2-(3-pyridinyl)- ethyl]amino]ethyl]phenyl]-1-(4-octylthiazol-2-yl)-5-indolinesulfonamide, on indices of metabolic and cardiovascular function were studied in anesthetized rhesus monkeys. Both compounds are potent and specific agonists at human and rhesus beta(3)-adrenergic receptors. Intravenous administration of either compound produced dose-dependent lipolysis, increase in metabolic rate, peripheral vasodilatation, and tachycardia with no effects on mean arterial pressure. The increase in heart rate in response to either compound was biphasic with an initial rapid component coincident with the evoked peripheral vasodilatation and a second more slowly developing phase contemporaneous with the evoked increase in metabolic rate. Because both compounds exhibited weak binding to and activation of rhesus beta(1)-adrenergic receptors in vitro, it was hypothesized that the increase in heart rate may be reflexogenic in origin and proximally mediated via release of endogenous norepinephrine acting at cardiac beta(1)-adrenergic receptors. This hypothesis was confirmed by determining that beta(3)-adrenergic receptor agonist-evoked tachycardia was attenuated in the presence of propranolol and in ganglion-blocked animals, under which conditions there was no reduction in the evoked vasodilatation, lipolysis, or increase in metabolic rate. It is not certain whether the beta(3)-adrenergic receptor-evoked vasodilatation is a direct effect of compounds at beta(3)-adrenergic receptors in the peripheral vasculature or is secondary to the release or generation of an endogenous vasodilator. Peripheral vasodilatation in response to beta(3)-adrenergic receptor agonist administration was not attenuated in animals administered mepyramine, indomethacin, or calcitonin gene-related peptide(8-37). These findings are consistent with a direct vasodilator effect of beta(3)-adrenergic receptor agonists.
Assuntos
Agonistas de Receptores Adrenérgicos beta 3 , Agonistas Adrenérgicos beta/farmacologia , Rubor/induzido quimicamente , Frequência Cardíaca/efeitos dos fármacos , Lipólise/efeitos dos fármacos , Reflexo/efeitos dos fármacos , Adenilil Ciclases/metabolismo , Anestesia , Animais , Células CHO , Cricetinae , Relação Dose-Resposta a Droga , Indometacina/farmacologia , Macaca mulatta , Masculino , Propanolaminas/farmacologia , Propranolol/farmacologiaRESUMO
As part of our investigation into the development of orally bioavailable beta(3) adrenergic receptor agonists, we have identified a series of pyridylethanolamine analogues possessing a substituted thiazole benzenesulfonamide pharmacophore that are potent human beta(3) agonists with excellent selectivity against other human beta receptor subtypes. Several of these compounds also exhibited an improved pharmacokinetic profile in dogs. For example, thiazole sulfonamide 2e (R = 4-F(3)C-C(6)H(4)) is a potent full beta(3) agonist (EC(50) = 3.6 nM, 94% activation) with >600-fold selectivity over the human beta(1) and beta(2) receptors, which also displays good oral bioavailability in several mammalian species, as well as an extended duration of action.
Assuntos
Agonistas de Receptores Adrenérgicos beta 3 , Agonistas Adrenérgicos beta/síntese química , Sulfonamidas/síntese química , Tiazóis/síntese química , Administração Oral , Agonistas Adrenérgicos beta/química , Agonistas Adrenérgicos beta/farmacocinética , Agonistas Adrenérgicos beta/farmacologia , Animais , Disponibilidade Biológica , Células CHO , Clonagem Molecular , Cricetinae , Cães , Glicerol/sangue , Humanos , Macaca mulatta , Masculino , Ensaio Radioligante , Ratos , Receptores Adrenérgicos beta 1/metabolismo , Receptores Adrenérgicos beta 2/metabolismo , Receptores Adrenérgicos beta 3/metabolismo , Relação Estrutura-Atividade , Sulfonamidas/química , Sulfonamidas/farmacocinética , Sulfonamidas/farmacologia , Tiazóis/química , Tiazóis/farmacocinética , Tiazóis/farmacologiaRESUMO
Genetic and pharmacological studies have defined a role for the melanocortin-4 receptor (Mc4r) in the regulation of energy homeostasis. The physiological function of Mc3r, a melanocortin receptor expressed at high levels in the hypothalamus, has remained unknown. We evaluated the potential role of Mc3r in energy homeostasis by studying Mc3r-deficient (Mc3r(-/-)) mice and compared the functions of Mc3r and Mc4r in mice deficient for both genes. The 4-6-month Mc3r-/- mice have increased fat mass, reduced lean mass and higher feed efficiency than wild-type littermates, despite being hypophagic and maintaining normal metabolic rates. (Feed efficiency is the ratio of weight gain to food intake.) Consistent with increased fat mass, Mc3r(-/-) mice are hyperleptinaemic and male Mc3r(-/-) mice develop mild hyperinsulinaemia. Mc3r(-/-) mice did not have significantly altered corticosterone or total thyroxine (T4) levels. Mice lacking both Mc3r and Mc4r become significantly heavier than Mc4r(-/-) mice. We conclude that Mc3r and Mc4r serve non-redundant roles in the regulation of energy homeostasis.
Assuntos
Tecido Adiposo/metabolismo , Peso Corporal , Receptores da Corticotropina/genética , Receptores da Corticotropina/fisiologia , Fatores Etários , Animais , Southern Blotting , Temperatura Corporal , Calorimetria , Corticosterona/biossíntese , Comportamento Alimentar , Feminino , Genótipo , Glucose/biossíntese , Humanos , Hiperinsulinismo/genética , Hibridização In Situ , Insulina/biossíntese , Leptina/biossíntese , Masculino , Camundongos , Camundongos Knockout , Modelos Genéticos , Atividade Motora , Obesidade/genética , Oligopeptídeos/farmacologia , Fenótipo , Isoformas de Proteínas , Receptor Tipo 3 de Melanocortina , Receptor Tipo 4 de Melanocortina , Receptores da Corticotropina/química , Receptores de Peptídeos/genética , Receptores de Peptídeos/metabolismo , Recombinação Genética , Tiroxina/biossíntese , Fatores de Tempo , Distribuição Tecidual , alfa-MSH/análogos & derivadosRESUMO
Compounds containing a 1,2,3-triazole-substituted benzenesulfonamide were prepared and found to be potent and selective human beta3-adrenergic receptor agonists. The most interesting compound, trifluoromethylbenzyl analogue 12e (beta3 EC50 = 3.1 nM with >1500-fold selectivity over binding to both beta1- and beta2 receptors), stimulates lipolysis in the rhesus monkey (ED50 = 0.36 mg/kg) and is 25% orally bioavailable in the dog.
Assuntos
Agonistas de Receptores Adrenérgicos beta 3 , Administração Oral , Animais , Disponibilidade Biológica , Células CHO , Cricetinae , AMP Cíclico/metabolismo , Cães , Relação Dose-Resposta a Droga , Humanos , Infusões Parenterais , Isoproterenol/farmacologia , Lipólise/efeitos dos fármacos , Macaca mulatta , Ligação Proteica , Receptores Adrenérgicos beta 3/metabolismo , Relação Estrutura-Atividade , Sulfonamidas/síntese química , Sulfonamidas/metabolismo , Sulfonamidas/farmacocinética , Taquicardia/induzido quimicamente , Triazóis/síntese química , Triazóis/metabolismo , Triazóis/farmacocinética , BenzenossulfonamidasRESUMO
A series of thiazole benzenesulfonamide-substituted 3-pyridylethanolamines was prepared and evaluated for their human beta3 adrenergic receptor agonist activity. Incorporation of aryl and heteroaryl substitution in the 4-position of the thiazole ring resulted in a number of highly potent and selective beta3 agonists. Results of preliminary in vivo evaluation of several of these compounds is described.
Assuntos
Agonistas de Receptores Adrenérgicos beta 3 , Agonistas Adrenérgicos beta/síntese química , Etanolaminas/síntese química , Sulfonamidas/síntese química , Tiazóis/síntese química , Agonistas Adrenérgicos beta/farmacologia , Animais , Células CHO , Cricetinae , Humanos , Relação Estrutura-Atividade , BenzenossulfonamidasRESUMO
We evaluated the role of the melanocortin-4 receptor (MC-4R) in the control of metabolic rate and food intake in mice. Intraperitoneal administration of the non-selective MC-R agonist melanotan II (MT-II; a cyclic heptapeptide) increases metabolic rate in wildtype mice, while MC-4R knockout mice are insensitive to the effects of MT-II on metabolic rate. MC-4R knockout mice are also insensitive to the effects of MT-II on reducing food intake. We conclude that MC-4R can mediate control of both metabolic rate and food intake in mice. We infer that a role for MC-3R in mediating the acute effects of MT-II on basal metabolic rate and food intake in wildtype mice seems limited.
Assuntos
Metabolismo Basal , Ingestão de Alimentos , Peptídeos Cíclicos/farmacologia , Receptores de Peptídeos/genética , Receptores de Peptídeos/metabolismo , alfa-MSH/análogos & derivados , alfa-MSH/farmacologia , Animais , Composição Corporal , Peso Corporal/fisiologia , Ingestão de Alimentos/fisiologia , Hibridização In Situ , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Atividade Motora , Receptor Tipo 4 de MelanocortinaRESUMO
As a part of our investigation into the development of orally bioavailable beta3 adrenergic receptor agonists, we have identified a series of substituted oxazole derivatives that are potent beta3 agonists with excellent selectivity against other beta receptors. Several of these compounds showed excellent oral bioavailability in dogs. One example, cyclopentylethyloxazole 5f is a potent beta3 agonist (EC50 = 14 nM, 84% activation) with 340-fold and 160-fold selectivity over beta1 and beta2 receptors, respectively, and has 38% oral bioavailability in dogs.
Assuntos
Agonistas de Receptores Adrenérgicos beta 3 , Agonistas Adrenérgicos beta/síntese química , Agonistas Adrenérgicos beta/farmacologia , Oxazóis/síntese química , Oxazóis/farmacologia , Sulfonamidas/farmacologia , Agonistas Adrenérgicos beta/química , Animais , Cães , Humanos , Indicadores e Reagentes , Cinética , Estrutura Molecular , Oxazóis/química , Relação Estrutura-Atividade , Sulfonamidas/síntese química , Sulfonamidas/químicaRESUMO
5-n-Pentyl oxadiazole substituted benzenesulfonamide 8 is a potent and selective beta3 adrenergic receptor agonist (beta3 EC50 = 23 nM, beta1 IC50 = 3000 nM, beta2 IC50 = 3000 nM). The compound has high oral bioavailability in dogs (62%) and rats (36%) and is among the most orally bioavailable beta3 adrenergic receptor agonists reported to date.
Assuntos
Agonistas de Receptores Adrenérgicos beta 3 , Agonistas Adrenérgicos beta/farmacologia , Agonistas Adrenérgicos beta/farmacocinética , Oxidiazóis/farmacologia , Oxidiazóis/farmacocinética , Administração Oral , Agonistas Adrenérgicos beta/administração & dosagem , Agonistas Adrenérgicos beta/química , Animais , Disponibilidade Biológica , Células CHO , Cricetinae , Cães , Desenho de Fármacos , Humanos , Estrutura Molecular , Oxidiazóis/administração & dosagem , Oxidiazóis/química , Ratos , Relação Estrutura-AtividadeRESUMO
Benzyl and phenoxymethylene substituted oxadiazoles are potent and orally bioavailable beta3 adrenergic receptor (AR) agonists. The 4-trifluormethoxy substituted 5-benzyl oxadiazole 5f has an EC50 of 8 nM in the beta3 AR agonist assay with 100-fold selectivity over beta1 and beta2 AR binding inhibition activity. Its oral bioavailability in dogs is 30 +/- 4%, with a half-life of 3.8 +/- 0.4 h. In the anesthetized rhesus, 5f evoked a dose-dependent glycerolemia (ED50Gly = 0.15 mg/kg). Under these conditions a heart rate increase of 15% was observed at a dose level of 10 mg/kg.
Assuntos
Agonistas de Receptores Adrenérgicos beta 3 , Agonistas Adrenérgicos beta/farmacologia , Fármacos Antiobesidade/farmacologia , Oxidiazóis/farmacologia , Sulfonamidas/farmacologia , Agonistas Adrenérgicos beta/síntese química , Agonistas Adrenérgicos beta/química , Animais , Fármacos Antiobesidade/síntese química , Fármacos Antiobesidade/química , Disponibilidade Biológica , Células CHO , Cricetinae , Cães , Desenho de Fármacos , Glicerol/metabolismo , Frequência Cardíaca/efeitos dos fármacos , Humanos , Macaca mulatta , Oxidiazóis/síntese química , Oxidiazóis/química , Relação Estrutura-Atividade , Sulfonamidas/síntese química , Sulfonamidas/químicaRESUMO
The anti-emetic profile of the novel brain penetrant tachykinin NK1 receptor antagonist MK-0869 (L-754,030) 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluor o)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine and its water soluble prodrug, L-758,298, has been examined against emesis induced by cisplatin in ferrets. In a 4 h observation period, MK-0869 and L-758,298 (3 mg/kg i.v. or p.o.) inhibited the emetic response to cisplatin (10 mg/kg i.v.). The anti-emetic protection afforded by MK-0869 (0.1 mg/kg i.v.) was enhanced by combined treatment with either dexamethasone (20 mg/kg i.v.) or the 5-HT3 receptor antagonist ondansetron (0.1 mg/kg i.v.). In a model of acute and delayed emesis, ferrets were dosed with cisplatin (5 mg/kg i.p.) and the retching and vomiting response recorded for 72 h. Pretreatment with MK-0869 (4-16 mg/kg p.o.) dose-dependently inhibited the emetic response to cisplatin. Once daily treatment with MK-0869 (2 and 4 mg/kg p.o.) completely prevented retching and vomiting in all ferrets tested. Further when daily dosing began at 24 h after cisplatin injection, when the acute phase of emesis had already become established, MK-0869 (4 mg/kg p.o. at 24 and 48 h after cisplatin) prevented retching and vomiting in three out of four ferrets. These data show that MK-0869 and its prodrug, L-758,298, have good activity against cisplatin-induced emesis in ferrets and provided a basis for the clinical testing of these agents for the treatment of emesis associated with cancer chemotherapy.
Assuntos
Acetais/farmacologia , Antieméticos/farmacologia , Antineoplásicos/farmacologia , Cisplatino/toxicidade , Morfolinas/farmacologia , Antagonistas dos Receptores de Neurocinina-1 , Pró-Fármacos/farmacologia , Vômito/tratamento farmacológico , Doença Aguda , Animais , Antieméticos/metabolismo , Aprepitanto , Células CHO , Células COS , Cricetinae , Relação Dose-Resposta a Droga , Furões , Humanos , Masculino , Morfolinas/metabolismo , Pró-Fármacos/metabolismo , Ratos , Receptores da Neurocinina-1/metabolismo , SolubilidadeRESUMO
The regioselective dibenzylphosphorylation of 2 followed by catalytic reduction in the presence of N-methyl-D-glucamine afforded 2-(S)-(1-(R)-(3, 5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(5-(2- phosphoryl-3-oxo-4H,-1,2,4-triazolo)methylmorpholine, bis(N-methyl-D-glucamine) salt, 11. Incubation of 11 in rat, dog, and human plasma and in human hepatic subcellular fractions in vitro indicated that conversion to 2 would be expected to occur in vivo most readily in humans during hepatic circulation. Conversion of 11 to 2 occurred rapidly in vivo in the rat and dog with the levels of 11 being undetectable within 5 min after 1 and 8 mg/kg doses iv in the rat and within 15 min after 0.5, 2, and 32 mg/kg doses iv in the dog. Compound 11 has a 10-fold lower affinity for the human NK-1 receptor as compared to 2, but it is functionally equivalent to 2 in preclinical models of NK-1-mediated inflammation in the guinea pig and cisplatin-induced emesis in the ferret, indicating that 11 acts as a prodrug of 2. Based in part on these data, 11 was identified as a novel, water-soluble prodrug of the clinical candidate 2 suitable for intravenous administration in humans.
Assuntos
Acetais/síntese química , Acetais/metabolismo , Anti-Inflamatórios não Esteroides/síntese química , Antieméticos/síntese química , Morfolinas/síntese química , Morfolinas/metabolismo , Antagonistas dos Receptores de Neurocinina-1 , Pró-Fármacos/síntese química , Acetais/química , Acetais/farmacologia , Animais , Anti-Inflamatórios não Esteroides/química , Anti-Inflamatórios não Esteroides/metabolismo , Anti-Inflamatórios não Esteroides/farmacologia , Antieméticos/química , Antieméticos/metabolismo , Antieméticos/farmacologia , Antineoplásicos , Aprepitanto , Cisplatino , Cães , Avaliação Pré-Clínica de Medicamentos , Furões , Cobaias , Humanos , Morfolinas/química , Morfolinas/farmacologia , Pró-Fármacos/química , Pró-Fármacos/metabolismo , Pró-Fármacos/farmacologia , Ratos , Solubilidade , Estereoisomerismo , Relação Estrutura-Atividade , Vômito/induzido quimicamente , Vômito/tratamento farmacológico , ÁguaRESUMO
L-770,644 (9c) is a potent and selective agonist of the human beta3 adrenergic receptor (EC50 = 13 nM). It shows good oral bioavailability in both dogs and rats (%F = 27), and is a full agonist for glycerolemia in the rhesus monkey (ED50 = 0.21 mg/kg). Based on its desirable in vitro and in vivo properties, L-770,644 was chosen for further preclinical evaluation.
Assuntos
Agonistas Adrenérgicos beta/administração & dosagem , Agonistas Adrenérgicos beta/síntese química , Agonistas Adrenérgicos beta/farmacologia , Sulfonamidas/administração & dosagem , Sulfonamidas/síntese química , Sulfonamidas/farmacologia , Tetrazóis/administração & dosagem , Tetrazóis/síntese química , Tetrazóis/farmacologia , Administração Oral , Animais , Disponibilidade Biológica , Cães , Humanos , Concentração Inibidora 50 , Cinética , RatosRESUMO
Human beta3 adrenergic receptor agonists containing 5-membered ring ureas were shown to be potent partial agonists with excellent selectivity over beta1 and beta2 binding. L-760,087 (4a) and L-764,646 (5a) (beta3 EC50 = 18 and 14 nM, respectively) stimulate lipolysis in rhesus monkeys (ED50 = 0.2 and 0.1 mg/kg, respectively) with minimal effects on heart rate. Oral absorption in dogs is improved over other urea analogs.
Assuntos
Agonistas Adrenérgicos beta/síntese química , Receptores Adrenérgicos beta/metabolismo , Administração Oral , Agonistas de Receptores Adrenérgicos beta 1 , Agonistas de Receptores Adrenérgicos beta 2 , Agonistas Adrenérgicos beta/farmacocinética , Agonistas Adrenérgicos beta/farmacologia , Animais , Cães , Frequência Cardíaca/efeitos dos fármacos , Humanos , Macaca mulatta , Receptores Adrenérgicos beta/efeitos dos fármacos , Receptores Adrenérgicos beta 3 , Relação Estrutura-Atividade , Sulfonamidas/síntese química , Sulfonamidas/farmacocinética , Sulfonamidas/farmacologia , Ureia/análogos & derivados , Ureia/síntese química , Ureia/farmacocinética , Ureia/farmacologiaRESUMO
The cyclopentylpropylimidazolidinone L-766,892 is a potent beta3 AR agonist (EC50 5.7 nM, 64% activation) with 420- and 130-fold selectivity over binding to the beta1 and beta2 ARs, respectively. In anesthetized rhesus monkeys, L-766,892 elicited dose-dependent hyperglycerolemia (ED50 0.1 mg/kg) with minimal effects on heart rate.
Assuntos
Agonistas Adrenérgicos beta/síntese química , Ciclopentanos/síntese química , Imidazóis/síntese química , Receptores Adrenérgicos beta/metabolismo , Agonistas de Receptores Adrenérgicos beta 1 , Agonistas de Receptores Adrenérgicos beta 2 , Agonistas Adrenérgicos beta/farmacocinética , Agonistas Adrenérgicos beta/farmacologia , Animais , Células CHO , Cricetinae , Ciclopentanos/farmacocinética , Ciclopentanos/farmacologia , Relação Dose-Resposta a Droga , Frequência Cardíaca/efeitos dos fármacos , Humanos , Imidazóis/farmacocinética , Imidazóis/farmacologia , Macaca mulatta , Receptores Adrenérgicos beta/efeitos dos fármacos , Receptores Adrenérgicos beta 3 , Relação Estrutura-AtividadeRESUMO
A model of acute lung injury induced by intravenous phorbol myristate acetate (PMA) is described. The model is characterized by the accumulation of polymorphonuclear leukocytes (PMNs) and a hemorrhagic edema in bronchoalveolar lavage (BAL) fluid when measured 6 h following the administration of PMA (60 microg/kg, i.v.). It was also determined that PMA induces acute leukopenia and neutropenia which were maximal at 5 min following the injection of PMA and were sustained for at least 6 h, with circulating leukocyte numbers returning to control values by 24 h. The extents to which the inflammatory and systemic changes induced by PMA were dependent on the surface expression on leukocytes of the beta2-integrins was assessed by comparing responses to PMA in control animals and animals pretreated with the anti-CD18 monoclonal antibody IB4. The administration of IB4 (1 mg/kg, i.v.) 15 min before PMA did not alter the time course or extent of PMA-induced leukopenia and neutropenia. In contrast IB4 administration (0.1 to 1 mg/kg) produced a dose dependent inhibition of PMN accumulation and plasma extravasation measured in BAL fluid. IB4 (1 mg/kg) completely inhibited PMA evoked increases in plasma extravasation (94.5 +/- 1.7%, N = 4) and hemorrhage (95.2 +/- 2.1%, N = 4) whereas PMN accumulation in BAL fluid was inhibited by 77.8 +/- 3.8% (mean +/- SEM, N = 4). Thus, a small, but reproducible, component of the PMA-induced PMN accumulation was not inhibited using this regimen of IB4 administration. If IB4 administration was delayed for 3 h post injection of PMA and bronchoalveolar lavage performed 3 h later, the extents of PMN accumulation and edema formation were similar to those observed 3 h following PMA challenge in control animals not dosed with IB4. This suggests that administration of IB4 during an ongoing inflammatory response is capable of preventing the further development of inflammatory changes and further supports the therapeutic potential of CD18 blockade in conditions such as adult respiratory distress syndrome.
Assuntos
Anticorpos Monoclonais/farmacologia , Antígenos CD18/imunologia , Endotélio Vascular/patologia , Neutrófilos/fisiologia , Acetato de Tetradecanoilforbol/farmacologia , Animais , Movimento Celular/efeitos dos fármacos , Endotélio Vascular/efeitos dos fármacos , Feminino , Contagem de Leucócitos/efeitos dos fármacos , Neutropenia/induzido quimicamente , Neutropenia/patologia , Neutrófilos/efeitos dos fármacos , CoelhosRESUMO
Structural modifications requiring novel synthetic chemistry were made to the morpholine acetal human neurokinin-1 (hNK-1) receptor antagonist 4, and this resulted in the discovery of 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-ox o-1 ,2,4-triazol-5-yl)methyl morpholine (17). This modified compound is a potent, long-acting hNK-1 receptor antagonist as evidenced by its ability to displace [125I]Substance P from hNK-1 receptors stably expressed in CHO cells (IC50 = 0.09 +/- 0.06 nM) and by the measurement of the rates of association (k1 = 2.8 +/- 1.1 x 10(8) M-1 min-1) and dissociation (k-1 = 0.0054 +/- 0.003 min-1) of 17 from hNK-1 expressed in Sf9 membranes which yields Kd = 19 +/- 12 pM and a t1/2 for receptor occupancy equal to 154 +/- 75 min. Inflammation in the guinea pig induced by a resiniferatoxin challenge (with NK-1 receptor activation mediating the subsequent increase in vascular permeability) is inhibited in a dose-dependent manner by the oral preadmininstration of 17 (IC50 (1 h) = 0.008 mg/kg; IC90 (24 h) = 1.8 mg/kg), indicating that this compound has good oral bioavailbility and peripheral duration of action. Central hNK-1 receptor stimulation is also inhibited by the systemic preadministration of 17 as shown by its ability to block an NK-1 agonist-induced foot tapping response in gerbils (IC50 (4 h) = 0.04 +/- 0.006 mg/kg; IC50 (24 h) = 0.33 +/- 0.017 mg/kg) and by its antiemetic actions in the ferret against cisplatin challenge. The activity of 17 at extended time points in these preclinical animal models sets it apart from earlier morpholine antagonists (such as 4), and the piperidine antagonists 2 and 3 and could prove to be an advantage in the treatment of chronic disorders related to the actions of Substance P. In part on the basis of these data, 17 has been identified as a potential clinical candidate for the treatment of peripheral pain, migraine, chemotherapy-induced emesis, and various psychiatric disorders.
Assuntos
Acetais/síntese química , Morfolinas/síntese química , Antagonistas dos Receptores de Neurocinina-1 , Acetais/administração & dosagem , Acetais/química , Acetais/farmacologia , Administração Oral , Animais , Aprepitanto , Comportamento Animal/efeitos dos fármacos , Ligação Competitiva , Células CHO , Permeabilidade Capilar/efeitos dos fármacos , Linhagem Celular , Cricetinae , Diterpenos/imunologia , Esôfago/irrigação sanguínea , Esôfago/efeitos dos fármacos , Esôfago/imunologia , Feminino , Furões , Gerbillinae , Membro Posterior/fisiologia , Humanos , Inflamação/imunologia , Inflamação/prevenção & controle , Masculino , Morfolinas/administração & dosagem , Morfolinas/química , Morfolinas/farmacologia , Traqueia/irrigação sanguínea , Traqueia/efeitos dos fármacos , Traqueia/imunologia , Bexiga Urinária/irrigação sanguínea , Bexiga Urinária/efeitos dos fármacos , Bexiga Urinária/imunologia , Vômito/prevenção & controleRESUMO
Previously reported studies from these laboratories described the design of a novel series of high-affinity NK1 antagonists based on the 4,4-disubstituted piperidine ring system. Further structure-activity studies have now established that for high NK1 affinity the benzyl ether side chain must be 3,5-disubstituted and highly lipophilic, the optimal side chain being the 3, 5-bis(trifluoromethyl)benzyl ether, 12 (hNK1 IC50 = 0.95 nM). Additional studies have shown that this class of NK1 antagonist tolerates a wider range of substituents on the piperidine nitrogen, including acyl (38) (hNK1 IC50 = 5.3 nM) and sulfonyl (39) (hNK1 IC50 = 5.7 nM) derivatives. Following preliminary pharmacokinetic analysis, two compounds (32 and 43) were selected for in vivo study in the resiniferotoxin-induced vascular leakage model, both showing excellent profiles (ID50 = 0.22 and 0.28 mg/kg, respectively).
Assuntos
Antagonistas dos Receptores de Neurocinina-1 , Piperidinas/síntese química , Pirrolidinas/síntese química , Tiazóis/síntese química , Animais , Células CHO , Permeabilidade Capilar/efeitos dos fármacos , Cricetinae , Diterpenos/toxicidade , Esôfago/irrigação sanguínea , Esôfago/efeitos dos fármacos , Cobaias , Fosfatos de Inositol/metabolismo , Masculino , Piperidinas/farmacocinética , Piperidinas/farmacologia , Pirrolidinas/farmacocinética , Pirrolidinas/farmacologia , Ensaio Radioligante , Receptores da Neurocinina-1/biossíntese , Relação Estrutura-Atividade , Tiazóis/farmacocinéticaRESUMO
The effects of beta-3 adrenergic receptor (beta3-AR) agonists on gastrointestinal (GI) motility, as reported by stomach retention and intestinal transit of radiolabelled charcoal, were compared in wild-type (WT) mice and in transgenic mice lacking beta3-AR (beta3-AR[KO]) or having beta3-AR in white and brown adipose tissue only (beta3-AR[WAT+BAT]). After s.c. administration of 3 mg/kg of the selective, rodent specific beta3-AR agonists BRL 35135, CL 316, 243 or ICI 198,157, WT mice exhibited a significant decrease in the extent of movement of radiotracer through the stomach and intestines, indicative of decreased GI motility. These compounds also caused an increase in plasma glycerol levels in the WT mice, suggesting that increased lipolysis in adipose tissue had been evoked. None of these compounds had an effect on GI motility or evoked lipolysis in the beta3-AR[KO] mice. Treatment of WT mice with SR 56811A, a beta3-AR agonist that exhibited a relatively lower affinity for rodent beta3-AR in vitro, did not affect GI motility or plasma glycerol levels in WT or beta3[KO] mice when administered s.c. at 3 mg/kg. Clonidine, an alpha-2 adrenergic receptor agonist, used as a positive control in these GI studies, caused a decrease in GI motility in both WT and beta3-AR[KO] mice. These results are consistent with a postulated role for beta3-AR in regulation of GI motility in the mouse. However, treatment of beta3-AR[WAT+BAT] mice with 3 mg/kg BRL 35135 resulted in elevated plasma glycerol levels, as well as increased stomach retention and decreased intestinal transit of radiotracer. These results suggest that this beta3-AR agonist may exert its effects on the GI tract indirectly, through an unknown signaling mechanism activated by agonism of beta3-AR in adipose tissue.